Literature DB >> 22704561

In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi.

Steeve Giguère1, Elise A Lee, Kristen M Guldbech, Londa J Berghaus.   

Abstract

There are no studies investigating interactions between clarithromycin or azithromycin and rifampin or other commonly used antimicrobial agents against virulent isolates of Rhodococcus equi. In addition, there is no published data on the postantibiotic effects (PAEs) and pharmacodynamics properties of antimicrobial agents against R. equi. The objectives were to assess in vitro interactions, pharmacodynamics, and PAEs of 11 antimicrobial agents belonging to various antimicrobial classes against R. equi. Antimicrobial agents investigated (erythromycin, clarithromycin, azithromycin, rifampin, amikacin, gentamicin, enrofloxacin, vancomycin, imipenem, ceftiofur, and doxycycline) were selected based on in vitro activity against large numbers of isolates of R. equi and frequency of use in foals or humans infected with R. equi. Three virulent strains of R. equi were evaluated by time-kill curves and checkerboard assays, and the postantibiotic effect was measured at 5×MIC. Only amikacin, gentamicin, enrofloxacin, and vancomycin were bactericidal against R. equi. Combinations including a macrolide (erythromycin, clarithromycin, azithromycin) and either rifampin or doxycycline, and the combination doxycycline-rifampin were synergistic. Combinations containing amikacin and erythromycin, clarithromycin, azithromycin, or rifampin and the combination gentamicin-rifampin were antagonistic. The PAEs of rifampin, erythromycin, clarithromycin, vancomycin, and doxycycline were relatively long with median values ranging between 4.5 and 6.5h. Azithromycin, gentamicin, and imipenem had intermediate PAEs ranging between 3.3 and 3.5h. Amikacin, enrofloxacin, and ceftiofur had shorter PAEs ranging between 1.3 and 2.1h. Gentamicin, amikacin, enrofloxacin, and doxycycline exhibited concentration-dependent activity whereas erythromycin, clarithromycin, azithromycin, rifampin, ceftiofur, imipenem, and vancomycin exhibited time-dependent activity against R. equi.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704561     DOI: 10.1016/j.vetmic.2012.05.031

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  12 in total

1.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  Antibacterial Characterization of Novel Synthetic Thiazole Compounds against Methicillin-Resistant Staphylococcus pseudintermedius.

Authors:  Haroon Mohammad; P V Narasimha Reddy; Dennis Monteleone; Abdelrahman S Mayhoub; Mark Cushman; G Kenitra Hammac; Mohamed N Seleem
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

3.  The anti-Staphylococcus aureus activity of the phenanthrene fraction from fibrous roots of Bletilla striata.

Authors:  Jing-Jing Guo; Bin-Ling Dai; Ni-Pi Chen; Li-Xia Jin; Fu-Sheng Jiang; Zhi-Shan Ding; Chao-Dong Qian
Journal:  BMC Complement Altern Med       Date:  2016-11-29       Impact factor: 3.659

4.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

5.  Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus.

Authors:  Huixian Chen; Ruoyu Mao; Da Teng; Xiumin Wang; Ya Hao; Xingjun Feng; Jianhua Wang
Journal:  AMB Express       Date:  2017-02-22       Impact factor: 3.298

6.  Mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A.

Authors:  Xueling Zheng; Xiumin Wang; Da Teng; Ruoyu Mao; Ya Hao; Na Yang; Lifen Zong; Jianhua Wang
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

7.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

8.  Unveiling the Mode of Action of Two Antibacterial Tanshinone Derivatives.

Authors:  Dongdong Wang; Wuxia Zhang; Tingting Wang; Na Li; Haibo Mu; Jiwen Zhang; Jinyou Duan
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

9.  In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Authors:  Elisa Rampacci; Maria Luisa Marenzoni; Elisabetta Chiaradia; Fabrizio Passamonti; Maurizio Ricci; Marco Pepe; Mauro Coletti; Stefano Giovagnoli
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

10.  Rhodococcus induced false-positive galactomannan (GM), a biomarker of fungal presentation, in patients with peritoneal dialysis: case reports.

Authors:  Tamonwan Chamroensakchai; Wasin Manuprasert; Asada Leelahavanichkul; Kullaya Takkavatakarn; Nisa Thongbor; Bunpring Jaroenpattrawut; Talerngsak Kanjanabuch
Journal:  BMC Nephrol       Date:  2019-12-02       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.